Galvani Bioelectronics is a clinical-stage company developing bioelectronic medicines through implant-based direct modulation of specific neural signals to organs central in chronic disease. The company's lead therapy targets Rheumatoid Arthritis via splenic nerve stimulation using a minimally invasive, laparoscopically implanted neuromodulation platform.